Aptose Biosciences Inc. Completes US$4.43M Registered Direct Offering and Concurrent Private Placement

On June 3, 2024, Aptose Biosciences Inc. ("Aptose") closed its previously announced registered direct offering of 3,855,000 common shares at a purchase price of US$1.15 per share. In the concurrent private placement, Aptose issued unregistered series A warrants to purchase up to 3,855,000 common shares and series B warrant to purchase up to 3,855,000 common shares, each at an exercise price of US$1.15 per share. The gross proceeds from the offering were approximately US$4.43 million.

Aptose, headquartered in San Diego, California, is a clinical-stage biotechnology company developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology.

McCarthy Tétrault advised Aptose with a team led by Charles-Antoine Soulière that included Farhiyah Shariff and Asma Boudoukha (Capital Markets).